{
    "title": "UK biotech firm PureTech abandons merger talks with US rival Nektar Therapeutics",
    "url": "https://www.dailymail.co.uk/money/markets/article-11303871/PureTech-abandons-merger-talks-rival-Nektar-Therapeutics.html",
    "date": "2022-10-11",
    "keywords": [
        "puretech",
        "share",
        "fund",
        "takeover",
        "period",
        "ftse",
        "biotechnology",
        "uncertainty",
        "end",
        "money",
        "diy",
        "platform",
        "investment",
        "account",
        "fee",
        "firm",
        "announcement",
        "impression",
        "stage",
        "potential",
        "cent",
        "city",
        "offer",
        "broker",
        "peel",
        "hunt",
        "weakness",
        "price",
        "entry",
        "point",
        "fibrosis",
        "tumours",
        "bowel",
        "syndrome",
        "depressionnektar",
        "meanwhile",
        "cancer",
        "autoimmune",
        "interest",
        "cost",
        "debt",
        "worst",
        "economy",
        "stability",
        "precipice",
        "bank",
        "england",
        "rate",
        "britain",
        "bargain",
        "grocery",
        "article",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing"
    ],
    "category": [
        "money",
        "markets"
    ]
}